New version of implanted neuromodulation device for HF launched
Click Here to Manage Email Alerts
CVRx announced it has launched a next-generation version of its neuromodulation device to treat HF symptoms.
The device (Barostim Neo2 IPG) is the second generation of the first FDA-approved neuromodulation system to treat HF, according to a press release issued by the company.
Compared with the first generation of the device, the second generation is 10% smaller, has 20% more battery life and has one instead of two lead ports to simplify the implantation procedure, according to the release.
“The new Barostim Neo2 offers the same clinically proven Barostim therapy, but with a more convenient design for my patients that is smaller and lasts longer,” Michael Hoosien, MD, electrophysiologist at Piedmont Atlanta, said in the release. “We are excited to use this next-generation system to further expand our Barostim program.”
As Healio previously reported, the next-generation programmer for the system was launched in July.
Read more about
Click Here to Manage Email Alerts